-+ 0.00%
-+ 0.00%
-+ 0.00%

VANDA PHARMACEUTICALS GRANTED ORPHAN DESIGNATION FOR IMSIDOLIMAB FOR THE TREATMENT OF GENERALIZED PUSTULAR PSORIASIS BY THE EUROPEAN COMMISSION

Reuters·08/24/2026 11:00:13

Please log in to view news